NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD
794.1
-104.85 (-11.66%)
The current stock price of LLY is 794.1 USD. In the past month the price decreased by -2.95%. In the past year, price increased by 8.05%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
JNJ | JOHNSON & JOHNSON | 15.37 | 372.23B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.96 | 291.20B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.21 | 219.89B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.95 | 218.61B | ||
MRK | MERCK & CO. INC. | 10.69 | 209.51B | ||
PFE | PFIZER INC | 7.45 | 135.72B | ||
SNY | SANOFI-ADR | 14.02 | 132.44B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.76 | 100.94B | ||
GSK | GSK PLC-SPON ADR | 7.05 | 78.52B | ||
ZTS | ZOETIS INC | 26.29 | 69.43B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.67 | 47.30B | ||
HLN | HALEON PLC-ADR | 21.08 | 46.61B |
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). The company also owns a lead therapeutic molecule FXR314.
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA 46285 US
CEO: David A. Ricks
Employees: 47000
Company Website: https://www.lilly.com/
Investor Relations: https://investor.lilly.com/
Phone: 13172762000
The current stock price of LLY is 794.1 USD. The price decreased by -11.66% in the last trading session.
The exchange symbol of ELI LILLY & CO is LLY and it is listed on the New York Stock Exchange, Inc. exchange.
LLY stock is listed on the New York Stock Exchange, Inc. exchange.
32 analysts have analysed LLY and the average price target is 1036.37 USD. This implies a price increase of 30.51% is expected in the next year compared to the current price of 794.1. Check the ELI LILLY & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELI LILLY & CO (LLY) has a market capitalization of 752.80B USD. This makes LLY a Mega Cap stock.
ELI LILLY & CO (LLY) currently has 47000 employees.
ELI LILLY & CO (LLY) has a support level at 739.73 and a resistance level at 884.55. Check the full technical report for a detailed analysis of LLY support and resistance levels.
The Revenue of ELI LILLY & CO (LLY) is expected to grow by 32.02% in the next year. Check the estimates tab for more information on the LLY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ELI LILLY & CO (LLY) has a dividend yield of 0.7%. The yearly dividend amount is currently 4.93. Check the full fundamental report for a detailed analysis of LLY dividend history, reliability and sustainability.
ELI LILLY & CO (LLY) will report earnings on 2025-05-01, before the market open.
The PE ratio for ELI LILLY & CO (LLY) is 61.08. This is based on the reported non-GAAP earnings per share of 13 and the current share price of 794.1 USD. Check the full fundamental report for a full analysis of the valuation metrics for LLY.
The outstanding short interest for ELI LILLY & CO (LLY) is 0.68% of its float. Check the ownership tab for more information on the LLY short interest.
ChartMill assigns a technical rating of 2 / 10 to LLY. When comparing the yearly performance of all stocks, LLY is one of the better performing stocks in the market, outperforming 74% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to LLY. While LLY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months LLY reported a non-GAAP Earnings per Share(EPS) of 13. The EPS increased by 105.7% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 23.51% | ||
ROA | 13.45% | ||
ROE | 74.62% | ||
Debt/Equity | 2.01 |
ChartMill assigns a Buy % Consensus number of 83% to LLY. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 78.29% and a revenue growth 32.02% for LLY